Benralizumab: a unique IL-5 inhibitor for severe asthma
Laren D Tan,1 Jennifer M Bratt,2 Dorottya Godor,3 Samuel Louie,2 Nicholas J Kenyon2 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department...
Main Authors: | Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | Journal of Asthma and Allergy |
Online Access: | https://www.dovepress.com/benralizumab-a-unique-il-5-inhibitor-for-severe-asthma-peer-reviewed-article-JAA |
Similar Items
-
Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
by: Brian J Lipworth, et al.
Published: (2023-12-01) -
Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
by: Shih-Lung Cheng
Published: (2021-07-01) -
Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab
by: Rory Chan, MBChB, PhD, et al.
Published: (2023-08-01) -
Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
by: Charlene Desaintjean, et al.
Published: (2024-03-01) -
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2023-06-01)